Observational studyBMC psychiatry2026
Socioeconomic burden of adult attention deficit/hyperactivity disorder in Japan: a nationwide cross-sectional observational study.
Observational study in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAttention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that negatively affects social, academic, and occupational functioning. Although more common in children, ~ 2.5% of adults worldwide have ADHD. In this cross-sectional observational study, we estimated the annual socioeconomic burden of adults with ADHD in Japan (societal perspective).
methodsWe used retrospective data from the JMDC claims database, a prospective web-based survey of adults with self-reported ADHD, adult family members living with an adult with ADHD, and adults without ADHD who had an Adult ADHD Self-Report Scale score < 4 (control population), and Japanese government agency websites to estimate medical costs (outpatient costs and drug costs), social welfare costs (disability pensions and employment support services), and productivity losses due to unemployment, low income, absenteeism, and presenteeism. In addition to the base-case analysis, we conducted scenario and sensitivity analyses to examine the effects of changing estimation and matching methods on costs, as well as a subgroup analysis of costs stratified by the number of psychiatric comorbidities.
resultsCost estimates were based on 30,730 adults with an ADHD diagnosis in the JMDC database and, from the web-based survey, 309 adults with self-reported ADHD, 309 adult family members of adults with ADHD, and 927 adults in the control population. Using an estimated 260,120 adults with ADHD in Japan, the base-case analysis estimated annual medical costs at 74.0 billion Japanese yen (JPY), social welfare costs at 389.6 billion JPY, and productivity losses at 571.1 billion JPY. Productivity losses in family members were estimated at 542.2 billion JPY. Total socioeconomic burden was estimated at 1.58 trillion JPY (~ US$10.9 billion) (~ 4 million JPY [~ US$29,000] per adult with ADHD). Social welfare costs and productivity losses increased with the number of comorbidities. In the scenario analyses, cost estimates varied from − 68.9% to + 96.1% relative to the base case and were most strongly affected by the method used to estimate the total number of adults with ADHD.
conclusionThis study, the first estimate of the annual socioeconomic burden of adult ADHD in Japan, underscores the necessity of more appropriate support for adult patients with ADHD and their families to reduce productivity losses.
trial registrationUniversity hospital Medical Information Network Center (UMIN000051654; registered July 20, 2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.